Cargando...

Bortezomib for the treatment of mantle cell lymphoma: an update

Bortezomib is a first in class proteasome inhibitor, initially approved by the US Food and Drug Administration for the treatment of plasma cell myeloma. Bortezomib has been approved for the treatment of relapsed and refractory mantle cell lymphoma (MCL) and, more recently, in the upfront setting as...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ther Adv Hematol
Main Authors: Hambley, Bryan, Caimi, Paolo F., William, Basem M.
Formato: Artigo
Idioma:Inglês
Publicado: SAGE Publications 2016
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4959639/
https://ncbi.nlm.nih.gov/pubmed/27493710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716648566
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!